PH-762, an INTASYL siRNA compound targeting PD-1, is being evaluated in an ongoing clinical trial (NCT 06014086) as a neoadjuvant intratumoral therapy for cutaneous malignancies, demonstrating ...

therapy in combination with radiotherapy is an effective treatment for late-stage nasopharyngeal carcinoma (NPC). The authors conclude that radiotherapy combined with intratumoral administration ...

The therapy was also effective in cancer models ... More information: Ahmed E. I. Hamouda et al, Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL ...

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation ...